A Comparison Of The IVF-ET Outcome With Different Dose A Long-acting GnRH-a (Enantone)

ObjectiveTo determine whether a lower than conventional dose of a long-acting Gonadotrophin-releasing hormone analogue(GnRH-a) may be more appropriate for use in vitro fertilization-embryo transfer (IVF-ET). MethodProspective studied the outcome of 56 cycles that performed IVF-ET, 28 cycles(A group) accepted a lower dose enantone(2mg), 28 cycles (B group) accepted conventional dose enantone(3.75mg). ResultsThe serum Luteinizing hormore (LH) level before useGonadotrophin (Gn) of A group was higher than that of B group(P=0.03), but there was no significant differences in LH level on the day of human chorionic gonadotropin (HCG) administration between two groups (P>0.05). There were no spontaneous premature LH surge in two groups. There were no significant differences between two groups either in the serum oestradiol(E₂) level before use Gn and on the day of HCG administration(P>0.05), number of Gn and stimulation days(P>0.05), nor in the number of oocytes retrieved, fertilization rate, embryo cleaved rate, pregnancy rate/cycle, pregnancy rate/transfer, miscarrige rate and implantation rate. ConclusionThe use of a lower dose enantone appears to be equally effective with the conventional dose on FVF-ET.